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Perceived vaccine safety 
A B S T R A C T   
As studies indicate that people perceive COVID-19 as a threatening disease, the demand for a vaccine against the 
disease could be expected to be high. Vaccine safety concerns might nevertheless outweigh the perceived disease 
risks when an individual decides whether or not to accept the vaccine. We investigated the role of perceived risk 
of COVID-19 (i.e., perceived likelihood of infection, perceived disease severity, and disease-related worry) and 
perceived safety of a prospective vaccine against COVID-19 in predicting intentions to accept a COVID-19 
vaccine. Three Finnish samples were surveyed: 825 parents of small children, 205 individuals living in an 
area with suboptimal vaccination coverage, and 1325 Facebook users nationwide. As points of reference, we 
compared the perceptions of COVID-19 to those of influenza and measles. COVID-19 was perceived as a 
threatening disease—more so than influenza and measles. The strongest predictor of COVID-19 vaccination 
intentions was trusting the safety of the potential vaccine. Those perceiving COVID-19 as a severe disease were 
also slightly more intent on taking a COVID-19 vaccine. Informing the public about the safety of a forthcoming 
COVID-19 vaccine should be the focus for health authorities aiming to achieve a high vaccine uptake.   
1. Introduction 
Due to the COVID-19 pandemic, the world faces a novel infectious 
disease, for which there currently is no treatment or herd immunity. The 
pandemic poses a serious threat to our health and well-being (WHO, 
2020a) and researchers are racing to develop and test vaccines against 
COVID-19 (Callaway, 2020). When vaccines become available, the 
success of the vaccination program will depend on the public’s accep-
tance of the vaccines. Recent studies have indicated that whereas the 
majority report they would accept a future vaccine against COVID-19 
(Blanchard-Rohner et al., 2020 [pre-print]; Detoc et al., 2020; Dodd 
et al., 2020; Faasse & Newby, 2020; Freeman et al., 2020; Malik et al., 
2020; Murphy et al., 2020 [pre-print]; Neumann-Böhme et al., 2020), 
6–25% report they would not (Detoc et al., 2020; Faasse & Newby, 2020; 
Murphy et al., 2020 [pre-print]; Neumann-Böhme et al., 2020; The 
COCONEL Group, 2020; Ward, Alleaume, Peretti-watel, & the COCO-
NEL Group, 2020). Understanding why people feel hesitant towards a 
vaccine against COVID-19 is of paramount importance, as this can help 
health authorities boost vaccine acceptance to limit the spread of the 
disease. Research shows that vaccine acceptance is a complex decision- 
making process influenced by a wide range of factors (for reviews, see e. 
g., Betsch et al., 2018; Brewer et al., 2017; Larson et al., 2014; Thomson 
et al., 2016). The present study will explore the role of two of these key 
factors—the perceived risk of the disease the vaccine protects against 
and the perceived safety of the vaccine—in people’s acceptance of a 
vaccine against COVID-19. 
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1.1. Perceived risk of disease 
A key determinant in people’s vaccination decisions is the risk they 
associate with the disease the vaccine protects against (Betsch et al., 
2018; Thomson et al., 2016). These risk perceptions are often measured 
as the perceived likelihood of contracting the disease and the perceived 
severity of the symptoms (Brewer et al., 2007). Risk perceptions are also 
generally considered to have an emotional dimension, including fear 
and worry (Loewenstein et al., 2001; Slovic et al., 2004). Research 
shows that individuals who perceive the risk of contracting a vaccine- 
preventable disease as low, consider the symptoms of the disease as 
mild, and worry little about the disease, report less intent to take the 
vaccines and more often remain unvaccinated (Betsch et al., 2018; Bish 
et al., 2011; Brewer et al., 2007; Schmid et al., 2017; Thomson et al., 
2016). 
The risks related to the novel corona virus SARS-CoV-2, which causes 
COVID-19, have been given considerable attention. On March 11th 
2020, the World Health Organization (WHO) declared the outbreak of 
COVID-19 a pandemic, calling for nations to take “urgent and aggres-
sive” action (WHO, 2020a). The pandemic is a global health crisis that 
has been covered extensively by the media, and governments and health 
authorities have taken extensive measures to control the spread of the 
disease. Therefore it is not surprising that recent studies show that 
people experience COVID-19 as a threatening disease (Dryhurst et al., 
2020; Faasse & Newby, 2020; Glöckner et al., 2020 [pre-print]; Kwok 
et al., 2020; Park et al., 2020; Wise et al., 2020). 
Looking at different aspects of perceived risk, studies have generally 
found that individuals who perceive COVID-19 to pose a greater risk 
engage more readily in preventive efforts, such as handwashing and 
social distancing (Dryhurst et al., 2020; Faasse & Newby, 2020; Harper 
et al., 2020; Wise et al., 2020). Investigating the relationship between 
risk perceptions and willingness to take a prospective vaccine against 
COVID-19, Malik et al. (2020) found that US respondents who rated the 
disease higher on a risk perception index (consisting of several risk 
measures) more often reported that they would accept a vaccine against 
COVID-19. Glöckner et al. (2020 [pre-print]) found that in a German 
sample, those who perceived their likelihood of becoming infected with 
COVID-19 as high and the health consequences of the disease as severe 
had higher vaccination intentions. By contrast, at an early stage of the 
pandemic, Faasse and Newby (2020) found in an Australian sample that 
perceived infection risk and perceived disease severity were not mean-
ingful predictors of COVID-19 vaccination intentions. Instead, the more 
the respondents worried about a widespread outbreak of COVID-19 in 
Australia, the higher their intentions were to take a COVID-19 vaccine. 
Also in a French sample, respondents who were very worried about 
contracting COVID-19 were more likely to agree to take a hypothetical 
COVID-19 vaccine (Ward et al., 2020). Taken together, the available 
research indicates that individuals who perceive the risk of COVID-19 as 
higher, report more willingness to take a prospective vaccine against the 
disease. However, there is disagreement among the studies concerning 
which risk-perception components are the most relevant. 
1.2. Perceived vaccine safety 
Another important factor in a vaccination decision is how safe the 
individual considers the vaccine to be. Individuals who perceive vac-
cines as safe are more likely to accept vaccinations (Betsch et al., 2018; 
MacDonald & the SAGE Working Group on Vaccine Hesitancy, 2015; 
Thomson et al., 2016). Because vaccines against COVID-19 are still 
under development, information about the safety of the vaccines is 
limited. Research, however, suggests that when there is a lack of infor-
mation and experience about the safety of a new vaccine, people tend to 
form their opinions based on attitudes to existing vaccines. This has been 
demonstrated for example in studies showing that attitudes to childhood 
vaccines predict intentions to use a hypothetical vaccine against the Zika 
virus (Harapan et al., 2019; Ophir & Jamieson, 2018). Another vaccine 
that might affect attitudes towards a COVID-19 vaccine is the Pandemrix 
vaccine. Pandemrix may be particularly relevant because it was imple-
mented during a pandemic of a new infectious disease, the swine flu, 
only a decade ago (2009–2010). The Pandemrix vaccine caused big 
controversy due to its association with an increased risk of narcolepsy 
(Sarkanen et al., 2018). In Finland, where the present study was con-
ducted, the connection between narcolepsy and the Pandemrix vaccine 
received a great deal of media attention and this may have exacerbated 
vaccine hesitancy, especially related to influenza vaccines. This hesi-
tancy might, in turn, affect the public’s trust in the safety of a potential 
vaccine against COVID-19. 
Another vaccine that has been subject to controversies and may 
affect the uptake of a COVID-19 vaccine is the MMR vaccine (against 
measles, mumps, and rubella). This is because a publication in 1998 
falsely suggested a link between the vaccine and autism. Although a 
large amount of research has since shown that the claim of a link is 
unsubstantiated, some individuals still have unwarranted fears about 
the vaccine (Karlsson et al., 2019; Wang et al., 2019). 
Paradoxically, vaccine safety concerns might be especially common 
when the prevalence of the vaccine-preventable disease is low and when 
vaccination programs have been successful. In those cases, the disease is 
not considered a high risk, and the perceived risks of vaccination might 
outweigh the perceived risks of the disease (Dubé et al., 2013; Kar-
afillakis & Larson, 2017; MacDonald & the SAGE Working Group on 
Vaccine Hesitancy, 2015). On the other hand, if the perceived disease 
risk is very high, individuals might decide to vaccinate despite vaccine 
concerns. 
1.3. The current study 
The current study includes three separate studies conducted in 
different samples of adults, which aimed 1) to obtain information on the 
perceived risk of COVID-19 and trust in the safety of a prospective 
vaccine against COVID-19 and, 2) to examine if the intention to take a 
vaccine against COVID-19 is related to the perceived risk of the disease 
and the perceived safety of the vaccine. As points of reference, the 
perceived risk of influenza and measles, as well as the perceived safety of 
the influenza and measles vaccines were also measured. 
To get a broad understanding of the role of perceived disease risk on 
vaccination intentions, and to cover most of the different aspects 
measured in previous studies, the following main components of 
disease-risk perceptions were explored: 1) perceived likelihood of 
infection, 2) perceived disease severity, and 3) disease-related worry. 
For perceived severity and worry, risk related to both oneself and others 
were measured. 
Study 1 focused on COVID-19 only. In parents of small children, the 
study investigated whether the perceived risk of the disease predicted 
intentions to take a potential COVID-19 vaccine recommended by au-
thorities. As COVID-19 has caused more severe symptoms and higher 
mortality among older individuals (Centers for Disease Control and 
Prevention, 2020), age was included as a proxy for objective risk. 
In Study 2, beyond replicating Study 1, we also measured the 
perceived risk of influenza and measles. Additionally, the study exam-
ined how willing individuals were to take a test-phase COVID-19 vac-
cine, and whether this willingness was predicted by disease-risk 
perceptions. The test-phase vaccine was included to represent a vaccine 
that is likely perceived as less safe, but where perceived disease risk is 
held constant (the vaccine also protects against COVID-19). The study 
was conducted in a sample living in an area with sub-optimal uptake of 
vaccines offered in the national vaccination program. 
Study 3 replicated Study 2 but extended the focus on perceived 
vaccine safety by including a measure on whether the respondents 
trusted that a prospective COVID-19 vaccine recommended by author-
ities would be safe. We also measured the perceived safety of the 
influenza and measles vaccines. Intentions to take vaccines against 
COVID-19 (i.e., a recommended vaccine and a test-phase vaccine) were 
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predicted by both perceived disease risk and perceived vaccine safety. 
Study 3 also included an additional measure of objective disease risk, 
that is, the prevalence of COVID-19, and investigated whether vacci-
nation intentions were higher among respondents living in a region 
where COVID-19 was more prevalent than among respondents living in 
other regions. The study was conducted in a nationwide sample of 
Facebook users. 
All studies were carried out during or directly after the first peak of 
the coronavirus pandemic in Finland. The data collection of Study 1 took 
place between May 4th and June 7th, 2020, Study 2 between March 
30th and April 12th, 2020, and Study 3 between April 3rd and 17th, 
2020. During Studies 2 and 3, the highest numbers of new COVID-19 
cases of the first pandemic wave (~900 per week) were observed, and 
the total number of cases more than doubled (Finnish Institute for 
Health and Welfare, 2020). Measures put in place by the Finnish gov-
ernment at the time included closing of schools, limiting public gath-
erings to a maximum number of 10 individuals, and prohibiting 
unnecessary travel to and from Uusimaa—the region with the most 
rapid increase in COVID-19 prevalence (Finnish Government, 2020a, 
2020b). During Study 1, the weekly incidence of COVID-19 decreased 
from 600 to 145. 
Because of the acute nature of the pandemic at the time of data 
collection, it was hypothesized that individuals would perceive COVID- 
19 to carry a greater risk compared to influenza and measles. Initial 
mortality estimates for COVID-19 provided by the WHO were also 
higher, at around 3.4%, compared to influenza and measles (mortality 
rates well under 1%; (Centers for Disease Control and Prevention, 2019; 
WHO, 2020b). It was also hypothesized that individuals who perceive 
the risk of COVID-19 as high (as measured by the three aspects of 
perceived risk) and trust that a prospective COVID-19 vaccine would be 
safe have higher intentions to vaccinate against COVID-19. Lastly, 
because the actual risk increases with age and prevalence of COVID-19, 
higher age and living in an area with higher COVID-19 prevalence were 
expected to be associated with higher vaccination intentions. 
2. General method 
All data were collected through surveys. The surveys mainly con-
sisted of questions probing topics related to the coronavirus pandemic. 
The relevant measures, which were developed by the authors, are pre-
sented in the following sections. 
3. Study 1 method 
3.1. Respondents and procedure 
In May 2020, 5103 parents from the FinnBrain Birth Cohort Study 
(Karlsson et al., 2018) were invited to an electronic survey including 
questions related to the coronavirus pandemic. The parents were asked 
to participate as they had previously (in 2018) been invited to a survey 
concerning attitudes to vaccines. The survey was open for five weeks. A 
total of 856 (16.8%) parents responded, but 31 (3.6%) did not answer 
the questions relevant for the present study and were excluded. The final 
sample size was, thus, 825. The mean age of the sample was 37.9 (SD =
4.75, range = 23–55; see Table S1 in the online supplemental material 
for demographics). Ethical approval for the study was obtained from the 
Ethics Committee of the Hospital District of Southwest Finland. Re-
spondents gave their informed consent to participate in the electronic 
survey. They did not receive any compensation for their participation. 
3.2. Measures 
3.2.1. Perceived disease risk 
The questions concerning perceived disease risk are presented in 
Table 1. We formulated the questions on perceived likelihood and 
severity of disease following the recommendations by Brewer et al. 
(2007). The respondents were asked to rate their likelihood of con-
tracting COVID-19 within the upcoming 12 months (perceived likelihood 
of infection). As previous research has indicated that a 7-point verbal 
Table 1 
Survey questions related to perceived disease risk.  
Measure Survey question Study 
COVID-19   
Perceived likelihood of infection I think that my likelihood of contracting COVID-19 during the following 12 months isa All 
Perceived severity: Personal How severe would it be for your health if you contracted COVID-19?b All 
Perceived severity: General How severe of a disease do you consider COVID-19 to be?b 1, 3  
COVID-19 is a very serious disease.c 2 
Perceived severity: Likelihood to 
die 
How likely do you think it is that a person who falls ill with COVID-19 dies as a result of the disease?a 3 
Worry: Fall ill How much do you worry about falling ill with COVID-19?d All 
Worry: Transmit How much do you worry about transmitting COVID-19 to someone else?d All 
Influenza   
Perceived likelihood of infection If I do not take the influenza vaccine, I think my likelihood of falling ill with influenza during the next season (2020− 2021) isa 2, 3 
Perceived severity: Personal How severe would it be for your health if you contracted influenza?b 2, 3 
Perceived severity: General Influenza is a very serious disease.c 2  
How severe of a disease do you consider influenza to be?b 3 
Perceived severity: Likelihood to 
die 
How likely do you think it is that a person who falls ill with influenza dies as a result of the disease?a 3 
Worry: Fall ill How much do you usually worry about falling ill with influenza?d 2, 3 
Worry: Transmit How much do you usually worry about transmitting influenza to someone else?d 2, 3 
Measles   
Perceived likelihood of infection If my child was unvaccinated against measles, I think the likelihood that my child falls ill with measles during the following 12 
months isa 
2, 3 
Perceived severity: Personal How severe would it be for your child(ren)’s health to contract measles?b 2, 3 
Perceived severity: General Measles is a very serious disease.c 2  
How severe of a disease do you consider measles to be?b 3 
Perceived severity: Likelihood to 
die 
How likely do you think it is that a person who falls ill with measles dies as a result of the disease?a 3 
Worry: Fall ill How much do you usually worry about your child(ren) falling ill with measles?d 2, 3 
Worry: Transmit How much do you usually worry about your child(ren) transmitting measles to someone else?d 2, 3  
a Response alternatives: 1–7 (virtually non-existent; virtually 100%). 
b Response alternatives: 1–5 (not severe at all; very severe). 
c Response alternatives: 1–6 (completely disagree; completely agree). 
d Response alternatives: 1–5 (not at all; very much). 
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scale for perceived likelihood of infection best predicts vaccination 
behavior (Weinstein et al., 2007), the response alternatives ranged from 
1 to 7 (1 = virtually non-existent, 2 = very small, 3 = small, 4 = medium 
sized, 5 = large, 6 = very large, 7 = virtually 100%). To measure perceived 
severity, the respondents were asked how severe they expected COVID- 
19 to be for their own health (perceived personal severity) and how 
severe of a disease they perceived COVID-19 to be in general (perceived 
general severity). The respondents answered on a scale from 1 to 5 (1 =
not severe at all, 2 = somewhat severe, 3 = quite severe, 4 = severe, 5 = very 
severe). Lastly, how much respondents worried about falling ill with or 
transmitting COVID-19 to someone else was measured on a scale from 1 
to 5 (1 = not at all, 2 = somewhat, 3 = quite much, 4 = much, 5 = very 
much). 
3.2.2. Vaccination intention 
To measure intentions to accept a vaccine against COVID-19, the 
respondents were asked “How likely do you consider it to be that you 
would take a vaccine against COVID-19, if such a vaccine was available, 
free of charge, and recommended to everyone by the authorities?”. 
Response alternatives ranged from 1 to 5 (1 = very unlikely, 2 = not that 
likely, 3 = hard to say, 4 = quite likely, 5 = very likely). 
3.3. Statistical analysis 
All analyses for Studies 1–3 were carried out in R, version 3.5.1 (R 
Core Team, 2018). In Study 1, we conducted a linear regression analysis 
with COVID-19 vaccination intentions as the outcome measure and the 
perceived disease-risk measures and age as predictors. Gender (1 = fe-
male; 2 = male) was included as a predictor because women have been 
found to perceive COVID-19 as a greater health risk than men (Galasso 
et al., 2020). On the other hand, the actual risk of COVID-19 has been 
found greater for men (Griffith et al., 2020). 
4. Study 1 results 
The parents’ responses to the question on intentions to take a rec-
ommended vaccine against COVID-19 are presented in Table 2. Fig. 1 
and Supplementary Table S2 show the distribution of responses to the 
five measures on the perceived risk of COVID-19. Zero-order correla-
tions between all measures can be found in Table 3. 
The results from the regression analysis (F[7, 771] = 4.78, p < .001, 
adjusted R2 = 0.03) are shown in Table 4. Of the perceived risk mea-
sures, only perceived general severity of the disease was statistically 
significantly associated with vaccination intentions (β = 0.12, p = .009). 
Respondents perceiving COVID-19 as more severe in general were more 
likely to accept the vaccine. Also, men were significantly more likely to 
intend to vaccinate against COVID-19 than women (β = 0.12, p < .001). 
5. Study 1 discussion 
Most parents did not expect COVID-19 to pose a great risk for their 
personal health although they considered the disease as severe and 
many worried about transmitting it to others. The majority of parents 
(73.9%) considered the likelihood that they would accept a vaccine 
against COVID-19 as high (response alternatives 4 and 5 on the 5-point 
scale), if such a vaccine were available and recommended by authorities. 
Interestingly, the only aspect of perceived disease risk that played a role 
in the respondents’ vaccination intentions was perceptions of the gen-
eral severity of COVID-19, so that those who perceived COVID-19 as a 
more severe disease were more likely to intend to vaccinate. Also, men 
had higher vaccination intentions than women. Both associations were, 
however, small. The model explained only 3% of the variance in 
vaccination intentions. None of the variables concerning the re-
spondents’ personal health predicted intentions to vaccinate. It is worth 
noting that the age distribution of the sample was narrow, and the re-
spondents were relatively young, with 96.4% being between 30 and 49 
years old (Supplementary Table S1). Study 1, therefore, suggested that 
the motivating factor to get vaccinated against COVID-19 is not related 
to how severe people perceive the disease to be for their own health, but 
rather to how serious they think the disease is for people in general—at 
least in this relatively young sample. 
Study 2 used a sample with a broader age range. In Study 2, people’s 
perceptions of COVID-19 were compared to those concerning influenza 
and measles. Vaccine safety was also included by examining how willing 
individuals were to accept a test-phase COVID-19 vaccine—a vaccine 
likely considered less safe because of the ongoing tests. 
6. Study 2 method 
6.1. Respondents and procedure 
In April 2019, 5000 18–65-year-old individuals living in the Pie-
tarsaari region in Finland were invited to an online survey on vaccine 
attitudes. The region was originally targeted because of the lower uptake 
of several vaccines included in the national vaccination program 
compared to other Finnish regions. A total of 1139 (22.8%) invitees 
responded to the survey and 335 (29.4%) consented to being contacted 
again and provided a valid e-mail address. On March 30th, 2020, these 
335 respondents were invited to an online survey on the coronavirus 
pandemic. The survey was open for two weeks and 205 (61.2%) in-
dividuals replied. No compensation for participation was provided. In 
Study 2, 110 (29.4%) respondents were between 50 and 65 years old 
(compared to Study 1, where 99% of the respondents were younger than 
50 years; see Supplementary Table S1 for sample descriptives), and 137 
(66.8%) reported having children. Ethical approval was received from 
the Board for Research Ethics at Åbo Akademi University. Informed 
consent to participate was given electronically. 
6.2. Measures 
6.2.1. Perceived disease risk 
Perceived likelihood of infection with, perceived severity of, and worry 
about COVID-19 were measured with the same questions and response 
alternatives as in Study 1, with the exception that the measure of 
perceived general severity was formulated as a statement instead of a 
question. The respondents indicated whether they agreed with the 
statement on a 6-point scale with the anchors 1 (completely disagree) and 
6 (completely agree). Additionally, corresponding questions related to 
influenza and measles were administered (Table 1). The measures of the 
perceived risk of COVID-19 were not administered if the respondent 
Table 2 
Responses to COVID-19 vaccination-intention questions in the three current 
studies.  
Variable Study 1 Study 2 Study 3 
n % n % n % 
Test-phase vaccine       
1 Very unlikely − − 66  34.02  407  30.95 
2 − − 37  19.07  227  17.26 
3 − − 57  29.38  283  21.52 
4 − − 25  12.89  249  18.94 
5 Very likely − − 9  4.64  149  11.33 
Recommended vaccine       
1 Very unlikely 33 4.32  8  4.12  159  12.05 
2 57 7.31  15  7.73  55  4.17 
3 114 14.62  20  10.31  143  10.84 
4 202 25.90  49  25.26  288  21.83 
5 Very likely 374 47.95  102  52.58  674  51.10 
Note. In Study 1, labels for the options 2 (not that likely), 3 (hard to say), and 4 
(quite likely) were provided. Study 1: 45 (5.5%) responses missing. Study 2: 11 
(5.4%) responses missing. Study 3: 10 (0.8%) responses missing concerning test- 
phase vaccine and 6 (0.5%) responses missing concerning recommended 
vaccine. 
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reported having tested positive for the disease. The questions related to 
measles were only administered to respondents who reported having 
children, except for the question on the general severity of measles that 
was presented to all respondents. 
6.2.2. Vaccination intention 
The question on intentions to accept a recommended COVID-19 
vaccine differed slightly from that in Study 1 and read: “Imagine a hy-
pothetical scenario where the authorities recommend a new vaccine 
against COVID-19 free of charge. How likely do you consider it to be that 
you would accept such a vaccine?”. Willingness to take a test-phase 
vaccine against COVID-19 was measured with the question: “Imagine 
a hypothetical scenario where you would be offered the possibility to 
participate in a trial of a new vaccine against COVID-19 that is under 
development. How likely do you consider it to be that you would accept 
such a vaccine?”. Respondents answered on a 5-point scale with the 
anchors 1 (very unlikely) and 5 (very likely). 
6.3. Statistical analyses 
We tested the difference between the respondents’ willingness to 
take a recommended COVID-19 vaccine and a test-phase vaccine using 
paired t-tests. Then, whether the perceived disease-risk measures, age, 
and gender (1 = female; 2 = male) predicted intentions to take a rec-
ommended COVID-19 vaccine and a test-phase vaccine was investigated 
in two linear regression analyses. In Study 2, the age measure was cat-
egorical, as the respondents reported which of the following age spans 
they belonged to: 18–29, 30–39, 40–49, or 50–59 years old, or 60+ years 
Fig. 1. Perceived disease risk and perceived vaccine 
safety. 
Violin plots of the responses to the questions on 
perceived risk of COVID-19 and the perceived safety 
of a recommended COVID-19 vaccine including dots 
for means and bars for standard deviations. For 
Studies 2 and 3, violin plots for influenza and measles 
are also presented. The outer borders of the violin 
shapes represent the frequency of responses.   
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old. The variable was dummy coded so that each age span was compared 
to the preceding age span. 
Additional analyses can be found in the online supplementary ma-
terial. In these analyses, we statistically tested the differences in risk 
perceptions between the diseases (Tables S4 and S5). Furthermore, we 
investigated whether intentions to take the influenza vaccine for oneself, 
and intentions to accept childhood vaccines for one’s children (Table S3) 
were predicted by their respective perceived risk measures, respondent 
age, and gender (Table S6). 
7. Study 2 results 
Table 2 shows the responses to the questions on COVID-19 vacci-
nation intentions. The distributions of responses to the questions on 
perceived disease risk are shown in Fig. 1 and in Supplementary Table 
S2. Zero-order correlations between all measures related to COVID-19 
are shown in Table 5. 
Respondents reported a significantly higher intention to take a rec-
ommended vaccine against COVID-19 than a test-phase vaccine (t[193] 
= 21.40, p < .001). The difference between the two types of vaccines 
was large (d = 1.53). 
The results from the two linear regression analyses with intentions to 
take a test-phase vaccine (F[10, 177] = 4.17, p < .001, adjusted R2 =
0.14) and a recommended vaccine (F[10, 177] = 5.31, p < .001, 
adjusted R2 = 0.19) against COVID-19 as outcomes are presented in 
Table 4. Respondents who perceived COVID-19 as a more severe disease 
(β = 0.23, p = .004), who worried more about transmitting COVID-19 (β 
= 0.19, p = .032), and who were male (β = 0.26, p < .001) were more 
likely to accept a test-phase COVID-19 vaccine. The same variables also 
significantly predicted willingness to accept a COVID-19 vaccine rec-
ommended by authorities, as those perceiving COVID-19 as more severe 
(β = 0.24, p = .002), who worried more about transmitting the disease 
(β = 0.26, p = .003), and male respondents (β = 0.23, p = .001) had 
higher intentions to accept a recommended vaccine. In addition, in-
dividuals in their 40s reported significantly higher intentions to accept 
the vaccine than those in their 30s (β = 0.24, p = .012). 
8. Study 2 discussion 
Respondents did not consider COVID-19 to constitute a high risk to 
their personal health, but the great majority (77.8%) considered the 
likelihood that they would take a recommended COVID-19 vaccine as 
high. Only ~18% reported a high likelihood for accepting a test-phase 
vaccine if offered. Considering the high acceptance of a recommended 
vaccine among the respondents, as well as their willingness to be con-
tacted for research purposes and the high response rate, this sample 
might not be representative of the general population in the Pietarsaari 
region. 
As in Study 1, the perceived risk of COVID-19 to the respondent’s 
own health did not predict vaccination intentions. Instead, those who 
believed that COVID-19 was a severe disease, worried about trans-
mitting it to others, and were male, were more likely to accept a test- 
phase and a recommended vaccine against COVID-19. The variables 
accounted for 14% of the variance in willingness to take a test-phase 
vaccine, and 19% of the variance in willingness to take a vaccine rec-
ommended by authorities. 
In summary, the results from Study 2 are in line with the conclusions 
from Study 1, suggesting that a more important factor in predicting 
whether people will accept a COVID-19 vaccine is how threatening they 
consider the disease to be to others than how threatening they consider 
it to be for themselves. This finding was even clearer in Study 2, where 
both variables that measured perceived risk of COVID-19 to others, 
played a role in the intentions to vaccinate. However, also these re-
spondents were relatively young with the majority being below 50 years 
of age. The low willingness to accept a test-phase vaccine indicates that 
when vaccine safety is less certain, vaccination rates might drop 
dramatically even though the disease is considered severe. 
Study 3 further examined the role of perceived vaccine safety by 
including a question probing how much the respondents trust that a 
recommended vaccine against COVID-19 would be safe. Study 3 also 
included an additional measure of perceived severity (the perceived 
likelihood of death from the disease) and an objective measure of disease 
risk (residing in Uusimaa vs. other Finnish region). 
9. Study 3 method 
9.1. Respondents and procedure 
Respondents were recruited via a marketed Facebook post with a link 
to an online survey. The post was marketed for two weeks, between the 
3rd and 17th of April 2020, and reached 97,408 Facebook users. The 
survey was viewed by 3305 (3.4%) individuals, of whom 2233 (67.6%) 
started to fill out the questionnaire. The 1325 individuals who reached 
the end of the questionnaire (i.e., had responded to questions on the last 
page of the survey) and answered correctly to an attention check 
question were included. Their mean age was 47.71 (SD = 13.11, range 
= 18–100; see, Supplementary Table S1 for sample descriptives). The 
Board for Research Ethics at Åbo Akademi University approved the 
study. Respondents gave their informed consent to participate in the 
study electronically. They did not receive any compensation for their 
participation. 
9.2. Measures 
9.2.1. Perceived disease risk 
The questions and response alternatives related to perceived likelihood 
of infection with, perceived severity of, and worry about COVID-19 
administered in Study 1 were administered in Study 3 as well 
(Table 1). The corresponding measures related to influenza and measles 
were the same as in Study 2, with the exception that the questions on 
perceived general severity of influenza and measles were reformulated 
to correspond to the COVID-19 question from Study 1. Furthermore, an 
additional measure of perceived severity for each disease was included, 
querying the likelihood of death from COVID-19/influenza/measles. 
Respondents gave their response on a scale from 1 to 7 (1 = virtually 
non-existent, 2 = very small, 3 = small, 4 = medium sized, 5 = large, 6 =
very large, 7 = virtually 100%). The questions on COVID-19 were not 
administered if the respondent reported having tested positive for the 
disease. The questions on measles were only administered to re-
spondents with children younger than 18. 
9.2.2. Perceived vaccine safety 
To measure perceptions of vaccine safety, respondents were pre-
sented with the statements “If a vaccine against COVID-19 became part 
Table 3 
Zero-order correlations between all measures in Study 1.  
Variable 1 2 3 4 5 6 7 
1. Perceived likelihood 
of infection 
–       
2. Perceived severity: 
Personal 
0.19 –      
3. Perceived severity: 
General 
0.18 0.52 –     
4. Worry: Fall ill 0.29 0.62 0.49 –    





0.08 0.09 0.12 0.05 0.04 –  
7. Age − 0.02 0.13 0.02 0.01 ¡0.09 0.10 – 
Note. Pearson’s r correlations. Bolded correlations are statistically significant at 
p < .05. 
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of the recommended vaccines in Finland, I would trust that it is safe”, 
“The influenza vaccines are safe”, and “The measles vaccine is safe”. 
They indicated whether they agree on a 5-point scale with the anchors 1 
(completely disagree) and 5 (completely agree). 
9.2.3. Disease prevalence 
During the time of the data collection, the Uusimaa region had a 
higher prevalence of COVID-19 than any other Finnish region. Move-
ment to and from Uusimaa was restricted by the government (Finnish 
Government, 2020b). The respondents were asked to indicate their re-
gion of residence. A variable coded as 1 if they reported living in 
Uusimaa, or 0 if they did not live in Uusimaa, was created. 
9.2.4. Vaccination intention 
The questions on intentions to accept a recommended vaccine and a 
test-phase vaccine against COVID-19 were the same as in Study 2. 
Table 4 
Predictors of COVID-19 vaccination intentions in the three current studies.  
Variable Standardized Unstandardized t p 
β 95% CI b 95% CI 
Study 1 
Recommended vaccinea       
Likelihood of infection 0.07 [− 0.00, 0.15] 0.07 [− 0.00, 0.14] 1.95 .052 
Perceived severity: Personal 0.04 [− 0.05, 0.13] 0.05 [− 0.07, 0.18] 0.86 .392 
Perceived severity: General 0.12 [0.03, 0.20] 0.14 [0.04, 0.25] 2.62 .009 
Worry: Fall ill − 0.05 [− 0.15, 0.06] − 0.06 [− 0.18, 0.07] 0.88 .379 
Worry: Transmit 0.02 [− 0.06, 0.11] 0.02 [− 0.06, 0.11] 0.51 .607 
Age 0.07 [− 0.00, 0.14] 0.02 [− 0.00, 0.03] 1.90 .057 
Gender 0.12 [0.05, 0.20] 0.35 [0.14, 0.55] 3.32 <.001  
Study 2 
Test-phase vaccineb       
Perceived likelihood of infection − 0.08 [− 0.07, 0.24] 0.09 [− 0.08, 0.25] 1.05 .296 
Perceived severity: Personal − 0.15 [− 0.33, 0.03] − 0.19 [− 0.41, 0.04] 1.66 .099 
Perceived severity: General 0.23 [0.08, 0.38] 0.26 [0.09, 0.44] 2.94 .004 
Worry: Fall ill 0.02 [− 0.16, 0.21] 0.03 [− 0.19, 0.25] 0.23 .817 
Worry: Transmit 0.19 [0.02, 0.36] 0.19 [0.02, 0.36] 2.16 .032 
Age: 30–39 vs. 18–29 − 0.15 [− 0.31, 0.00] − 0.50 [− 0.99, 0.00] 1.97 .050 
Age: 40–49 vs. 30–39 0.02 [− 0.16, 0.21] 0.06 [− 0.39, 0.51] 0.25 .800 
Age: 50–59 vs. 40–49 0.18 [− 0.03, 0.39] 0.46 [− 0.09, 1.02] 1.65 .101 
Age: 60+ vs. 50–59 0.02 [− 0.16, 0.20] 0.06 [− 0.54, 0.66] 0.20 .839 
Gender 0.26 [0.12, 0.41] 0.69 [0.31, 1.06] 3.64 <.001 
Recommended vaccineb       
Perceived likelihood of infection 0.09 [− 0.06, 0.24] 0.09 [− 0.06, 0.25] 1.19 .237 
Perceived severity: Personal − 0.05 [− 0.23, 0.12] − 0.06 [− 0.27, 0.14] 0.59 .554 
Perceived severity: General 0.24 [0.09, 0.39] 0.26 [0.10, 0.42] 3.19 .002 
Worry: Fall ill 0.03 [− 0.15, 0.21] 0.04 [− 0.17, 0.24] 0.37 .711 
Worry: Transmit 0.26 [0.09, 0.42] 0.25 [0.09, 0.41] 3.06 .003 
Age: 30–39 vs. 18–29 − 0.06 [− 0.21, 0.09] − 0.19 [− 0.65, 0.27] 0.83 .408 
Age: 40–49 vs. 30–39 0.24 [0.05, 0.42] 0.54 [0.12, 0.96] 2.55 .012 
Age: 50–59 vs. 40–49 − 0.13 [− 0.34, 0.07] − 0.33 [− 0.85, 0.18] 1.27 .206 
Age: 60+ vs. 50–59 0.04 [− 0.13, 0.22] 0.14 [− 0.41, 0.70] 0.50 .616 
Gender 0.23 [0.09, 0.37] 0.57 [0.23, 0.92] 3.28 .001  
Study 3 
Test-phase vaccinec       
Perceived likelihood of infection 0.07 [0.01, 0.13] 0.08 [0.01, 0.14] 2.29 .022 
Perceived severity: Personal 0.03 [− 0.06, 0.11] 0.03 [− 0.07, 0.14] 0.62 .534 
Perceived severity: General − 0.04 [− 0.12, 0.05] − 0.06 [− 0.18, 0.06] 0.91 .361 
Perceived severity: Likelihood to die 0.09 [0.02, 0.16] 0.10 [0.02, 0.19] 2.42 .016 
Worry: Fall ill − 0.03 [− 0.12, 0.05] − 0.04 [− 0.13, 0.06] 0.77 .442 
Worry: Transmit 0.00 [− 0.08, 0.07] 0.00 [− 0.09, 0.09] 0.02 .985 
Perceived vaccine safety 0.51 [0.46, 0.57] 0.56 [0.50, 0.63] 17.22 <.001 
Prevalence 0.04 [− 0.01, 0.09] 0.12 [− 0.04, 0.27] 1.51 .132 
Age 0.14 [0.09, 0.20] 0.02 [0.01, 0.02] 4.89 <.001 
Gender 0.08 [0.02, 0.13] 0.27 [0.08, 0.47] 2.80 .005 
Recommended vaccined       
Perceived likelihood of infection 0.05 [0.01, 0.90] 0.06 [0.01, 0.10] 2.42 .016 
Perceived severity: Personal 0.06 [− 0.01, 0.12] 0.07 [− 0.01, 0.14] 1.79 .073 
Perceived severity: General 0.07 [0.01, 0.13] 0.10 [0.02, 0.19] 2.42 .016 
Perceived severity: Likelihood to die 0.00 [− 0.05, 0.05] 0.00 [− 0.06, 0.06] 0.01 .990 
Worry: Fall ill 0.03 [− 0.03, 0.09] 0.03 [− 0.04, 0.10] 0.90 .371 
Worry: Transmit − 0.00 [− 0.06, 0.05] − 0.01 [− 0.07, 0.06] 0.17 .863 
Perceived vaccine safety 0.72 [0.68, 0.76] 0.78 [0.73, 0.82] 33.67 <.001 
Prevalence 0.00 [− 0.03, 0.04] 0.01 [− 0.10, 0.12] 0.15 .878 
Age 0.04 [0.00, 0.09] 0.00 [0.00, 0.01] 2.13 .034 
Gender 0.04 [− 0.00, 0.08] 0.13 [− 0.01, 0.26] 1.82 .069 
Note. List-wise deletion of missing values. Statistically significant results are bolded. Gender coded as 1 = female and 2 = male. 
a n = 779. 
b n = 188. 
c n = 973. 
d n = 977. 
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9.3. Statistical analysis 
As in Study 2, we compared the respondents’ intentions to take a 
recommended and a test-phase COVID-19 vaccine using paired t-tests. 
Two linear regression analyses were then conducted—one with the 
recommended COVID-19 vaccine as the outcome, and another with the 
test-phase COVID-19 vaccine as the outcome. The outcomes were 
regressed on the measures of perceived risk, perceived vaccine safety, 
disease prevalence, age, and gender (1 = female; 2 = male). The addi-
tional analyses conducted in Study 2 were conducted in Study 3 as well 
(see, online supplemental material). 
10. Study 3 results 
Responses to the questions on COVID-19 vaccination intentions are 
shown in Table 2. The distribution of the responses to the questions on 
perceived risk and perceived vaccine safety are shown in Fig. 1 and 
Supplementary Table S2. Zero-order correlations between all measures 
related to COVID-19 are presented in Table 6. 
The difference between the respondents’ willingness to take a rec-
ommended vaccine and a test-phase vaccine against COVID-19 was 
statistically significant and large (t[1314] = 40.20, p < .001, d = 1.11). 
Table 4 shows the results from the two regression analyses on pre-
dictors of willingness to take a test-phase (F[10, 962] = 55.04, p < .001, 
adjusted R2 = 0.36) and a recommended vaccine against COVID-19 (F 
[10, 966] = 201.60, p < .001, adjusted R2 = 0.67). Respondents who 
perceived the likelihood of contracting COVID-19 as higher (β = 0.07, p 
= .022), the likelihood of death from COVID-19 as higher (β = 0.09, p =
.016), those who trusted the safety of a prospective vaccine more (β =
0.51, p < .001), and men (β = 0.08, p = .005) reported significantly more 
willingness to accept a test-phase vaccine. In addition, higher age was 
related to a higher willingness to take a test-phase vaccine (β = 0.14, p <
.001). Concerning the recommended COVID-19 vaccine, respondents 
who perceived the likelihood of contracting the disease as higher (β =
0.05, p = .016), who considered COVID-19 a more severe disease (β =
0.07, p = .016), who had higher trust in the vaccine being safe (β = 0.72, 
p < .001), and who were older (β = 0.04, p = .034) were significantly 
more likely to accept vaccination. 
11. Study 3 discussion 
The majority of the respondents (72.9%) considered the likelihood 
that they would accept a vaccine against COVID-19 as high, if such a 
vaccine was offered and recommended by authorities. When it comes to 
a test-phase vaccine, ~30% considered the likelihood high that they 
would agree to the vaccine. Vaccine safety showed the strongest rela-
tionship with vaccination intentions, explaining 52% of unique variance 
in intentions to accept a recommended COVID-19 vaccine. The measures 
of perceived risk of COVID-19 were weakly related to vaccination in-
tentions. As in Studies 1 and 2, the perceived severity measures that 
reached statistical significance probed the perceived risk of COVID-19 to 
people in general, and not specifically to oneself. Those perceiving 
COVID-19 as a severe disease were slightly more likely to intend to take 
a recommended vaccine, whereas those perceiving the likelihood of 
death from COVID-19 as higher were slightly more willing to accept a 
test-phase vaccine. Contrary to the results of Studies 1 and 2, the re-
spondents’ perceived risk to contract COVID-19 also predicted vacci-
nation intentions. However, the perceived risk measures accounted for 
only 0.2–0.8% of the variance in vaccination intentions. The objective 
risk of contracting COVID-19 was not associated with people’s willing-
ness to vaccinate, as there was no difference in vaccination intentions 
between those living in Uusimaa and those living in regions with lower 
COVID-19 prevalence. 
Furthermore, the older the respondents were, the more likely they 
were to intend to take the two types of vaccines. The fact that age pre-
dicted vaccination intentions in Study 3, but not in Studies 1 and 2, 
might stem from the fact that Study 3 included a sample with the 
broadest age range. Also, the power in Study 3 was higher, allowing us 
to detect smaller effects. Finally, men were slightly more likely to accept 
a test-phase vaccine than women, whereas there were no significant 
gender differences in intention to take a recommended COVID-19 
vaccine. 
12. General discussion 
The aims of the present study were 1) to examine people’s percep-
tions of the risk of COVID-19 and the safety of a prospective vaccine 
against COVID-19, and 2) to investigate if the perceived disease risk and 
Table 5 
Zero-order correlations between measures related to COVID-19 in Study 2.  
Variable 1 2 3 4 5 6 7 8 
1. Perceived likelihood of infection –        
2. Perceived severity: Personal 0.22 –       
3. Perceived severity: General 0.10 0.42 –      
4. Worry: Fall ill 0.30 0.57 0.34 –     
5. Worry: Transmit 0.44 0.30 0.21 0.50 –    
6. Vaccination intentions: Recommended vaccine 0.17 0.13 0.27 0.18 0.29 –   
7. Vaccination intentions: Test-phase vaccine 0.09 0.05 0.18 0.07 0.19 0.50 –  
8. Age − 0.08 0.28 0.25 0.04 − 0.04 0.15 0.15 – 
Note. Pearson’s r correlations. Bolded correlations are statistically significant at p < .05. 
Table 6 
Zero-order correlations between measures related to COVID-19 in Study 3.  
Variable 1 2 3 4 5 6 7 8 9 10 
1. Perceived likelihood of infection –          
2. Perceived severity: Personal 0.41 –         
3. Perceived severity: General 0.37 0.68 –        
4. Perceived severity: Likelihood die 0.37 0.63 0.67 –       
5. Worry: Fall ill 0.46 0.77 0.65 0.60 –      
6. Worry: Transmit 0.46 0.51 0.59 0.50 0.63 –     
7. Vaccine safety 0.22 0.34 0.48 0.33 0.36 0.37 –    
8. Vaccination intentions: Recommended vaccine 0.27 0.40 0.50 0.35 0.41 0.39 0.81 –   
9. Vaccination intentions: Test-phase vaccine 0.16 0.25 0.29 0.25 0.23 0.22 0.58 0.61 –  
10. Age ¡0.12 0.23 0.23 0.16 0.10 ¡0.06 0.21 0.21 0.25 – 
Note. Pearson’s r correlations. Bolded correlations are statistically significant at p < .05. 
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perceived vaccine safety are related to intentions to take a COVID-19 
vaccine. As a point of reference, we also measured perceptions of 
influenza and measles. 
Across the current three studies, individuals commonly considered 
COVID-19 to be a very severe disease, although they expected to expe-
rience less severe symptoms themselves. Individuals also worried more 
about transmitting the disease to others than about falling ill personally. 
Previous research has found an optimistic bias in risk ratings of COVID- 
19, as individuals commonly consider their own risks as smaller 
compared to others (Park et al., 2020). 
Approximately ¾ of the individuals considered the likelihood that 
they would accept a recommended vaccine against COVID-19 to be high 
(i.e., chose the response alternatives 4 or 5 on the 5-point scale; 73.9% in 
the sample of parents, 77.8% in the sample in the Pietarsaari region, and 
72.9% in the nationwide sample of Facebook users). Other studies have 
found acceptance rates of 67% in the US (Malik et al., 2020), 81–86% in 
Australia (Dodd et al., 2020; Faasse & Newby, 2020), and between 62 
and 85% in other European countries (Blanchard-Rohner et al., 2020 
[pre-print]; Murphy et al., 2020 [pre-print]; Neumann-Böhme et al., 
2020). For the test-phase vaccine, the acceptance rates were 17.5% and 
30.3% in the present study. 
12.1. Predictors of vaccination intentions 
Importantly, the strongest predictor of intentions to accept a COVID- 
19 vaccine recommended by authorities was the degree to which re-
spondents trusted the vaccine to be safe. Perceived vaccine safety 
explained 52% of the variance in intentions to vaccinate. Across the 
three studies, how serious the respondents thought COVID-19 was for 
people in general also predicted higher vaccination intentions, but the 
predictive value was much smaller (explaining 0.5–5.8% of the variance 
in intention to accept a recommended COVID-19 vaccine). Taken 
together, this means that individuals who perceive the disease as severe 
might still choose not to vaccinate if they consider the vaccine unsafe. 
However, individuals who perceive the vaccine as safe might be willing 
to take the vaccine although they would not consider the disease as 
severe (Fig. 2 visualizes this relationship). In the present study, 15.4% of 
respondents reported that they did not trust a vaccine against COVID-19 
recommended by authorities to be safe, and another 15.4% were unsure. 
The fact that the acceptance rates of a test-phase vaccine, which might 
be considered less safe, were considerably lower than those of the rec-
ommended vaccines also suggests that vaccine safety plays a major role 
in willingness to take a COVID-19 vaccine. A recent study of seven Eu-
ropean countries found that the majority of individuals who were unsure 
about whether they would accept a COVID-19 vaccine or not, and those 
who would reject the vaccine, expressed fear of side effects as the reason 
for their hesitancy (Neumann-Böhme et al., 2020). Concerns about 
vaccine safety can, thus, be expected to constitute the largest future 
challenge for health authorities when trying to achieve a high uptake of 
a COVID-19 vaccine. 
Contrary to expectations, the perceived risk of COVID-19 to one’s 
personal health was not robustly associated with intentions to vaccinate. 
This contrasts with previous research that has found higher perceived 
likelihood of infection (Glöckner et al., 2020 [pre-print]) and more 
worry about contracting COVID-19 (Ward et al., 2020) to predict higher 
vaccination intentions. However, Faasse and Newby (2020) also found 
the risk of COVID-19 to one’s personal health to be only weakly related 
to vaccination intentions. The fact age did not show any considerable 
(linear) association with vaccine acceptance further supports the notion 
that personal disease risk plays a minor role in the vaccination decision. 
Even when someone does not expect to experience severe symptoms of 
COVID-19 themselves, they might still be motivated to vaccinate to 
protect others from a potentially severe disease. 
The practical implication of the above-mentioned results is that, to 
ensure sufficient uptake of an approved COVID-19 vaccine, communi-
cations that underscore the safety of the vaccine are more important 
than highlighting the risks of the disease. It is, however, worth noting 
that perceived vaccine safety was moderately correlated with how se-
vere the respondents perceived COVID-19 to be for people in general. 
Those who perceived the disease as mild, often also perceived the vac-
cine as unsafe (Fig. 2). If this is because people evaluate the safety of the 
vaccine in relation to how severe they perceive the disease to be, then it 
is possible that communication emphasizing the risks of the disease in-
fluence vaccine perceptions. However, it is also possible that the rela-
tionship between perceived vaccine safety and perceived severity of 
COVID-19 could be explained by a third variable, such as general lack 
of trust in information provided by medical authorities. 
As respondent age and prevalence of COVID-19 did not show any 
notable relationship with intentions to accept a recommended COVID- 
19 vaccine, the present study also suggests that communication on 
vaccine safety should be directed towards individuals at all ages and 
geographical areas. Women were less willing to accept COVID-19 
vaccination than men, but the size of the gender difference varied be-
tween studies, and most of the differences were small. Specifically tar-
geting women in communication on a COVID-19 vaccine might, 
therefore, not be essential. 
12.2. Limitations 
The present study had some limitations. First, the cross-sectional 
design did not allow for robust conclusions concerning causality. Sec-
ond, the fact that the data collections took place during the first peak of 
the pandemic can be considered both a strength and a limitation. On the 
one hand, it provided information on individuals’ perceptions of COVID- 
19 during acute circumstances. However, vaccinations against COVID- 
19 might be introduced at a stage of the pandemic when individuals 
have been habituated to the threat. Research conducted during the 
swine flu pandemic indicated that the perceived risk of the swine flu 
decreased as the pandemic progressed (Bults et al., 2015). Glöckner 
et al. (2020 [pre-print]) conducted three cross-sectional studies in Ger-
many during the growth stage of the COVID-19 pandemic and when the 
Fig. 2. COVID-19 vaccination intentions. Perceived general severity of COVID- 
19 (y-axis) plotted by perceived safety of a prospective COVID-19 vaccine (x- 
axis) in Study 3. The degree to which the respondents report being likely to 
accept a vaccine against COVID-19 recommended by authorities is represented 
by blue (response alternative 4 or 5 on the scale ranging from 1[very unlikely] to 
5 [very likely]), green (response alternative 3), and red (response alternative 1 
or 2) dots. Marginal distributions are represented by rugs. (For interpretation of 
the references to color in this figure legend, the reader is referred to the web 
version of this article.) 
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growth curve flattened. They found that perceived risk of COVID-19 
decreased after the pandemic peak. Acceptance rates and associations 
need to be repeatedly studied as the pandemic develops. 
Third, the measures administered were developed by the authors and 
had not been independently validated. However, the formulation of the 
questions related to the perceived likelihood and severity of disease 
followed recommendations on the development of reliable risk- 
perception measures (Brewer et al., 2007). The remaining measures 
corresponded to those commonly used in research on the subject. We 
therefore place confidence in our measures. 
Fourth, we did not measure the exact age of respondents in Study 2. 
The respondents were instead asked to indicate which ten-year age span 
they belonged to. To account for this, age was dummy coded for the 
analyses. 
Lastly, there were minor discrepancies between the studies in some 
of the measures. There were two reasons for these discrepancies: 1) the 
samples in Studies 1 and 2 were part of longitudinal studies and we 
formulated the questions to enable comparison between the two time 
points, and 2) in Study 1, the vaccination intention measure was adapted 
to correspond to the structure of a larger COVID-19 survey. 
12.3. Conclusions 
Across three Finnish samples, individuals perceived COVID-19 as a 
severe disease and worried about transmitting it to others. Respondents 
were, however, less concerned about the risk of the disease to their own 
health, especially in the younger samples. Approximately ¾ of re-
spondents reported they would take a vaccine against COVID-19, if such 
a vaccine was available and recommended by authorities. The strongest 
predictor of having high intentions to take a COVID-19 vaccine was 
trusting the vaccine to be safe. Higher vaccination intentions were also 
somewhat more likely for respondents perceiving the disease as more 
severe, than for those considering COVID-19 as a mild disease. 
Informing the public about the safety of a forthcoming vaccine is of 
paramount importance to health authorities planning to roll out large- 
scale vaccinations in the near future. Highlighting the fact that 
COVID-19 can have detrimental health consequences for those infected, 
may also positively affect vaccine uptake although the magnitude of that 
effect may be smaller. 
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Beyond confidence: Development of a measure assessing the 5C psychological 
antecedents of vaccination. PLoS ONE, 13(12), 1–32. https://doi.org/10.1371/ 
journal.pone.0208601. 
Bish, A., Yardley, L., Nicoll, A., & Michie, S. (2011). Factors associated with uptake of 
vaccination against pandemic influenza: A systematic review. Vaccine, 29(38), 
6472–6484. https://doi.org/10.1016/j.vaccine.2011.06.107. 
Blanchard-Rohner, G., Caprettini, B., Rohner, D., & Voth, H. (2020). Impact of COVID-19 
and health system performance on vaccination hesitancy: Evidence from a two-leg 
representative survey in the UK. SSRN Electronic Journal, 1–40. https://doi.org/ 
10.2139/ssrn.3627335. 
Brewer, N. T., Chapman, G. B., Gibbons, F. X., Gerrard, M., McCaul, K. D., & 
Weinstein, N. D. (2007). Meta-analysis of the relationship between risk perception 
and health behavior: The example of vaccination. Health Psychology, 26(2), 136–145. 
https://doi.org/10.1037/0278-6133.26.2.136. 
Brewer, N. T., Chapman, G. B., Rothman, A. J., Leask, J., & Kempe, A. (2017). Increasing 
vaccination: Putting psychological science into action. Psychological Science in the 
Public Interest, 18(3), 149–207. https://doi.org/10.1177/1529100618760521. 
Bults, M., Beaujean, D. J. M. A., Richardus, J. H., & Voeten, H. A. C. M. (2015). 
Perceptions and behavioral responses of the general public during the 2009 
influenza A (H1N1) pandemic: A systematic review. Disaster Medicine and Public 
Health Preparedness, 9(2), 207–219. https://doi.org/10.1017/dmp.2014.160. 
Callaway, E. (2020). The race for coronavirus vaccines: A graphical guide. Nature, 580, 
576–577. https://doi.org/10.1038/d41586-020-01221-y. 
Centers for Disease Control and Prevention. (2019). Complications of measles. Retrieved 
from https://www.cdc.gov/measles/symptoms/complications.html?CDC_AA_refVa 
l=https%3A%2F%2Fwww.cdc.gov%2Fmeasles%2Fabout%2Fcomplications.html. 
Centers for Disease Control and Prevention. (2020). Coronavirus Disease 2019 (COVID- 
19): Older adults. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/n 
eed-extra-precautions/older-adults.html. 
Detoc, M., Bruel, S., Frappe, P., Tardy, B., Botelho-Nevers, E., & Gagneux-Brunon, A. 
(2020). Intention to participate in a COVID-19 vaccine clinical trial and to get 
vaccinated against COVID-19 in France during the pandemic. Vaccine, 38, 
7002–7006. https://doi.org/10.1016/j.vaccine.2020.09.041. 
Dodd, R., Cvejic, E., Bonner, C., Pickles, K., & McCaffery, K. (2020). Willingness to 
vaccinate against COVID-19 in Australia. The Lancet Infectious Diseases. https://doi. 
org/10.1016/S1473-3099(20)30559-4. 
Dryhurst, S., Schneider, C. R., Kerr, J., Freeman, A. L. J., Recchia, G., van der Bles, A. M., 
… van der Linden, S. (2020). Risk perceptions of COVID-19 around the world. 
Journal of Risk Research, 1–13. https://doi.org/10.1080/13669877.2020.1758193. 
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